Caris Life Sciences, Inc.CAIEarnings & Financial Report
Caris Life Sciences is a leading precision medicine biotech company specializing in advanced molecular profiling for oncology. It provides actionable genomic and molecular insights to oncologists to personalize cancer treatment plans, and partners with biopharmaceutical firms to accelerate novel cancer drug discovery and development, serving customers across North America, Europe, and key Asia-Pacific markets.
CAI Q3 FY2025 Key Financial Metrics
Revenue
$216.8M
Gross Profit
N/A
Operating Profit
$32.6M
Net Profit
$24.3M
Gross Margin
N/A
Operating Margin
15.1%
Net Margin
11.2%
YoY Growth
113.4%
EPS
$0.08
Caris Life Sciences, Inc. Q3 FY2025 Financial Summary
Caris Life Sciences, Inc. reported revenue of $216.8M (up 113.4% YoY) for Q3 FY2025, with a net profit of $24.3M (up 135.9% YoY) (11.2% margin).
Key Financial Metrics
| Total Revenue | $216.8M |
|---|---|
| Net Profit | $24.3M |
| Gross Margin | N/A |
| Operating Margin | 15.1% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
Caris Life Sciences, Inc. Q3 FY2025 revenue of $216.8M breaks down across 2 segments, led by Molecular Profiling Services at $207.6M (95.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Molecular Profiling Services | $207.6M | 95.7% |
| Pharma Research And Development Services | $9.2M | 4.3% |
Caris Life Sciences, Inc. Revenue by Segment — Quarterly Trend
Caris Life Sciences, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Molecular Profiling Services and Pharma Research And Development Services) has evolved quarter over quarter.
| Segment | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | Q2 FY2024 |
|---|---|---|---|---|
| Molecular Profiling Services | $207.6M | $162.9M | — | — |
| Pharma Research And Development Services | $9.2M | $18.5M | — | — |
Caris Life Sciences, Inc. Quarterly Revenue & Net Profit History
Caris Life Sciences, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $216.8M | +113.4% | $24.3M | 11.2% |
| Q2 FY2025 | $181.4M | +81.3% | $-71.8M | -39.6% |
| Q3 FY2024 | $101.6M | — | $-67.7M | -66.6% |
| Q2 FY2024 | $100.0M | — | $-66.2M | -66.2% |
Income Statement
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | $100.0M | $101.6M | $181.4M | $216.8M |
| YoY Growth | N/A | N/A | 81.3% | 113.4% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Assets | N/A | N/A | $955.1M | $984.6M |
| Liabilities | N/A | N/A | $502.2M | $506.2M |
| Equity | $-2.36B | $-2.44B | $452.9M | $478.4M |
Cash Flow
| Q3 2025 | |
|---|---|
| Operating CF | $62.4M |